News

Chiesi and Recordati ready for new acquisitions

Pharmaceuticals: Chiesi ready for new shopping

ROMA (MF-DJ) – There could be some news for Chiesi in the coming months. The president of the group, Alberto Chiesi, told CorrierEconomia, explaining that “we are interested in taking over innovative projects, products and companies. In particular we are interested in the areas of rare diseases and specialist diseases, both in the USA and in Europe. In the next few months we want to carry out some acquisitions”. “We are looking at something concrete - continued Chiesi- outside of Italy”. So far the family has gone on its own. “Of course -explained the chairman- if we were faced with the opportunity of acquiring companies of our size, if not larger, we would be forced to resort to external capital, and therefore to consider options such as the Stock Exchange. But I think we can go one step at a time." Also because on major mergers, Chiesi defined himself as “sceptical. I don't think there are many mergers that have created real and useful synergies for the company, in most cases we end up adding up turnovers and organisations”.

MF-DJ NEWS 1609:37 Nov 2015 – CorSera 16/11/2015

Recordati, now two acquisitions. ally? It doesn't have to be taboo

The Monday insert of Corriere della Sera interviewed Giovanni Recordati, number one of the homonymous company listed on Piazza Affari. The manager of the pharmaceutical company indicated that the top management is working to complete two acquisitions in Europe over the next few quarters “to strengthen the group in the business of traditional products, those over the counter. But also the unreimbursed OTCs”. The operations will not be large but will be "very targeted", exploiting available cash for 240 million euros against long-term debts for 300 million. Recorati's goal is to bring the group's turnover from the 1.04 billion euro estimated for the current year to 1.2 billion. Giovanni Recordati highlighted that "in the last 15 years the group has invested one billion in acquisitions and distributed dividends of 500 million".

SoldiOnLine – 11/16/2015

Related news: Recordati: president, ready for 2 acquisitions

LEO Pharma acquires Astellas dermatological medicines

Redazione Fedaiisf

Promote the cohesion and union of all members to allow a univocal and homogeneous vision of the professional problems inherent in the activity of pharmaceutical sales reps.

Articoli correlati

Back to top button
Fedaiisf Federazione delle Associazioni Italiane degli Informatori Scientifici del Farmaco e del Parafarmaco